within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD02_MetforminAndSulfonylureas;

model MetforminAndSulfonylureas
  extends Pharmacolibrary.Drugs.ATC.A.A10BD02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination products containing metformin (a biguanide antihyperglycemic agent) and sulfonylureas (insulin secretagogues) are used to treat type 2 diabetes mellitus. These combinations leverage complementary mechanisms: metformin decreases hepatic glucose production and increases insulin sensitivity, while sulfonylureas stimulate insulin release from pancreatic beta cells. Such combinations are approved and widely used as oral diabetic medications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult patients with type 2 diabetes. No published clinical PK model specific for the fixed drug combination found; parameters presented as estimated from individual component literature for typical oral dosing.</p><h4>References</h4><ol><li><p>Devineni, D, et al., &amp; Usiskin, K (2015). Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. <i>Clinical pharmacology in drug development</i> 4(3) 226–236. DOI:<a href=\"https://doi.org/10.1002/cpdd.166\">10.1002/cpdd.166</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27140803/\">https://pubmed.ncbi.nlm.nih.gov/27140803</a></p></li><li><p>Pearson, ER (2009). Pharmacogenetics in diabetes. <i>Current diabetes reports</i> 9(2) 172–181. DOI:<a href=\"https://doi.org/10.1007/s11892-009-0028-3\">10.1007/s11892-009-0028-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19323963/\">https://pubmed.ncbi.nlm.nih.gov/19323963</a></p></li><li><p>Halas, CJ (2001). Nateglinide. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 58(13) 1200–1205. DOI:<a href=\"https://doi.org/10.1093/ajhp/58.13.1200\">10.1093/ajhp/58.13.1200</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11449877/\">https://pubmed.ncbi.nlm.nih.gov/11449877</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndSulfonylureas;
